, the pioneer in developing therapeutic filtration devices to address infectious disease and cancers, announced today that it has filed a provisional patent on behalf of its wholly possessed subsidiary Exosome Sciences, Inc. , associated with the advancement of an assay that may allow experts to detect exosomes in blood and other fluids. Beyond the potential therapeutic great things about getting rid of immunosuppressive exosomes from circulation, researchers recognize that exosomes represent an important diagnostic target to determine progression and prognosis of both cancers and infectious disease circumstances. The company’s Enzyme Linked Lectin Specific Assay can be analogous to the well established enzyme connected immunosorbent assay , and offers been made to bind particularly to carbohydrate structures common to exosomes, however, not to healthy individual cellular components.We enjoy the FDA’s thoughtful responses to our questions and their invitation to begin with planning for the Phase 3 clinical system through the SPA process.in June 2010 ‘, results from a well planned interim analysis of the ongoing Stage 2b RESTORE-CLI scientific trial were announced at the Culture for Vascular Surgery annual meeting. Contained in the total results was the accomplishment of statistical significance on amputation-free survival. Critical limb ischemia , the most unfortunate form of peripheral vascular disease, prospects to over 160,000 major limb amputations per year in the U.S.